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(3,584 cancers, 88,514 genital warts annually). Head and neck cancers represent the
majority of additional cancers avoided. Boys’ vaccination would allow a further
reduction in females’ cases thanks to indirect protection. CONCLUSIONS: Model
simulations were robust as they replicated US published results. This first analysis
showed that vaccinating boys in addition of girls had the potential to prevent a
significant number of additional cases. Country specific analysis will be useful to
take into account different vaccination programs in place.
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OBJECTIVES: Since the inception of economic evaluation for new drug reimburse-
ment decisions in 2007, there have been modifications on this policy. While this
reflects in itself the imperfect systematic adoption of economic evaluation from
the beginning, it has been pointed out that the current scheme relying on the proof
of cost-effectiveness value remains silent on crucial issues related to the opportu-
nity cost from a system perspective and fair access to treatment. This study was
aimed to discover how much social judgment was prudently considered in the
reimbursement decision process especially for oncology medications in Korea.
METHODS: Public review documents drawn by the Health Insurance Review and
Assessment Agency on oncology medications were collected and analyzed to ex-
amine the concrete shape of public accountability. For external comparison, cor-
responding public documents presented by the Pharmaceutical Benefits Advisory
Committee of Australia and the National Institute for Health and Clinical Excel-
lence of UK were also pulled together and analyzed. Finally, not only clinical and
economic evidence factors but also non-evidentiary factors such as equity and
historical precedent revealed through the analytical works were discussed in depth
by interviewing oncologists as representative stakeholders. RESULTS: Among 12
cancer drugs, five received positive decision from January, 2007 to June, 2009. Clin-
ical study data and price of drugs seemed the mostly considered standard for
reimbursement decision. The social judgment in this study implied the reconsid-
eration on the following issues: 1) the composition of Drug Reimbursement Evalu-
ation Committee; 2) the rationale of using cost-effectiveness data; 3) equity for rare
cancer patients; 4) words clarity in public documents; 5) transparent decision pro-
cess; and 6) budget impact results. CONCLUSIONS: Besides focusing on the im-
provement of technical evidence in HTA, a greater effort should be made for the
reasonable decision process reflecting societal desirability, public agreement and
judgments on social value.
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OBJECTIVES: Anti-cancer drug formulary has been managed by the government in
Korea and needs to be updated for better clinical outcomes. This study was to
evaluate current anti-cancer drug formulary focusing on pancreatic neuroendo-
crine tumors (PNET) and then propose the new formulary reimbursement criteria.
METHODS: The drugs on the formulary and the drugs approved for the treatment
of PNET were reviewed whether their use and reimbursement was appropriate in
the view of the evidence-based approach. The oncology textbooks and clinical
practice guidelines were reviewed also. PubMed search for the primary drug liter-
ature was performed with MeSH terms (pneuroendocrine tumors, pancreatic neo-
plasms, islet cell adenoma, islet cell carcinoma, and gastro-enteropancreatic neu-
roendocrine tumor) and the limits (clinical trial, and publication date to April 30,
2011). Published clinical research data were critically rated with the pre-deter-
mined literature evidence strength levels and the new formulary was proposed.
RESULTS:Only one anti-cancer drug (sunitinib) was approved in Korea, although it
was not proposed as a first-line in the clinical guidelines (NCCN, ESMO) and a
textbook (Abeloff’s). Although it was not on the national formulary list, a recently
published randomized controlled phase 3 trial would support its use in a certain
type of PNET as a primary chemotherapy. The already listed drugs revealed to be
evidence-supported but with relatively weak strength levels. National formulary
appeared to be reformulated with refined criteria (drug dosage and cancer types,
etc). CONCLUSIONS: Sunitinib should be listed on the national anti-cancer drug
formulary with a restricted reimbursement criteria of “treatment of unresectable
or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease
progression in adults” as described in the approved indication and pivotal clinical
research data. Next step of the research of this area would be to examine clinical
outcomes with this formulary change.
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OBJECTIVES: Cervical cancer is the third most common gynecologic cancer in the
United States. Currently there are two proven approaches to cervical cancer pre-
vention: conventional cytology screening and human papillomavirus (HPV) vacci-
nation. Prevention guidelines recommend screening every one to three years after
onset of sexual activity. In addition, many states have passed legislation to require
mandatory HPV vaccination for school children. The study aims to compare the
cost-effectiveness of HPV vaccination combined with conventional cytology
screening versus HPV vaccination alone on cervical cancer prevention in the US.
METHODS:A decision tree was used to estimate the lifetime costs (in 2004 US$) and
outcomes for U.S. women receiving HPV vaccination or mandatory HPV vaccina-
tion combined with conventional cytology screening from the societal perspective.
The costs and epidemiological data were derived from published literature and
health institution websites. Outcomes included life expectancy and quality-ad-
justed life years (QALYs) gained. RESULTS: The incremental cost-effectiveness ra-
tio (ICER) for HPV vaccination combined with the triennial screening compared to
vaccination alone was $251,965 per QALY gained. The result was most sensitive to
the total costs of conventional cytology screening. When the total costs of conven-
tional cytology screening varied from $30 to $319, the ICER increased from $98,669
to $1,006,860 per QALY gained. When increasing the frequency of screening to
biennial and annual, the ICER of HPV vaccination combined with screening com-
pared to vaccination alone changed to $335,533 and $592,991 per QALY gained
respectively. CONCLUSIONS: These results indicate that conventional cytology
screening provides little benefit beyond that provided by HPV vaccination. They
suggest that routine cytology screening should no longer be recommended for
women who have been successfully vaccinated.
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OBJECTIVES: Expensive hospital anti-cancer drugs are funded separately from the
activity-based payments. Reimbursement tariffs are set for a list of drugs including
a large proportion of anti-cancer drugs. This funding aims to ensure equity of
access to innovation throughout the French territory. Our objective was to describe
the use of the expensive anti-cancer drugs in French hospitals and to investigate
whether differences existed between the public and private sector and between
regions. METHODS: We used a sample of 448 hospitals authorized to deliver che-
motherapies. The Groupement pour l’Elaboration et la Réalisation de Statistique
provided the sales per drug and per hospital in the year 2008. Hospital character-
istics were extracted from two national surveys (Programme de Médicalisation des
Systèmes d’Information and Statistique Annuelle des Etablissements de santé). We
conducted a multilevel analysis. The dependent variable was the mean expendi-
ture per chemotherapy session and per hospital. Independent variables were hos-
pital capacity, the volume of activity, case-mix for chemotherapies and the per-
centage use of biological drugs. At the regional level, we used the mean annual
wage, inequality of wage distribution, the density of general practitioners, cancer
incidence and mortality. RESULTS: The sales of anti-cancer drugs were estimated
at 1713 million Euros. The mean expenditure per chemotherapy session was € 923
[CI: 890-954]. It was significantly higher in the private sector: €970 versus €891,
p0.02. At the hospital level, a case-mix of specialized chemotherapies for breast
cancers and the percentage use of biological drugs were associated with a higher
expenditure of anti-cancer drugs per session. There were no differences between
the mean expenditures per region. CONCLUSIONS: The absence of disparities in
the use of anti-cancer drugs between regions suggests that the reimbursement
tariffs have promoted equal access to innovative treatments throughout the terri-
tory.
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OBJECTIVES: To estimate direct annual healthcare utilization and costs of for pa-
tients with head and neck cancer. METHODS: The 2008 Medical Expenditure Panel
Survey (MEPS) database, a nationally representative annual survey of the civilian
non-institutionalized population of the U.S was used. Patients’ data were extracted
if they had a Clinical Classification Code (CCC) for head and neck cancer (code 11)
and International Classification of Disease 9 (ICD-9) code of 140.xx-149.xx or
160.xx-161.xx. The SURVEYREG procedure in SAS for weighted populations was
used. RESULTS: Only 17 patients (representing 223,263 persons) met inclusion cri-
teria, therefore weighting may not be robust. Direct unweighted medical costs
attributable to cancer were estimated at $6,171  11,288 (mean  standard devia-
tion) per patient. Approximately half ($ 2860 6399) of this estimate was generated
by outpatient costs. Physician office visits ($1,609 4,291) and inpatient hospital
visits ($1225 5054) contributed to most of the remaining costs. If MEPS weightings
were used, the total costs were estimated at $ 8629 - again with about half gener-
ated by outpatient costs, and the majority of remaining costs split between office
visits and hospitalizations. Since MEPS only provides 3 digits of the 5-digit ICD-9,
some patients may have been missed as we did not include some ICD9s listed by
CCC 11; such as 195.xx “Malignant neoplasm of other and ill-defined sites” nor
230.xx “Carcinoma in situ of digestive organs” which included some cancers re-
lated to the head and neck (e.g. 230.0 - Carcinoma in situ of lip oral cavity and
pharynx) as well as others not related to these areas (e.g. 230.3 - Carcinoma in situ
of colon). CONCLUSIONS: The sample size was small in this database. Future stud-
ies should be conducted using databases with more patients and/or a more precise
level of diagnosis coding.
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UNDERLYING CAUSES FOR SUB-OPTIMAL UTILISATION OF CANCER DRUGS
FUNDS IN ENGLAND
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